Treatment of tumors using specific anti-L1 antibody

US9260521B2 · kind B2 · utility

Assignees

• Medi&Gene Inc. · DE
• DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS · DE

Inventors

• Daniela Kelm · Dossenheim, DE
• Peter Altevogt · Trochtelfingen, DE
• Gerhard Moldenhauer · Heidelberg, DE
• Frank Breitling · Heidelberg, DE
• Achim R. Krueger · Cherry Hill, US
• Silke Baerreiter · Weinheim, DE
• Sandra Luettgau · Schongau, DE
• Ulrich Moebius · Gauting, DE
• Yi Li · Shanghai, CN
• Susanne Sebens · Kiel, DE
• Heiner Schaefer · Kiel, DE

Key dates

• Filing date: Oct 3, 2013
• Grant date: Feb 16, 2016
• Expiry date: Apr 1, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment.